Nov. 10, 2009 - AMA Softens Position on Scheduling of Marijuana The American Medical Association softens its position on medical marijuana in a policy statement released Nov. 10, 2009. The statement read in part: Our AMA urges that marijuanas status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods. This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product. Prior to the Nov. 10, 2009 position quoted above, the AMA had recommended that marijuana be retained in Schedule I of the Controlled Substances Act pending the outcome of further studies. American Medical Association (AMA) AMA Policy: Medical Marijuana, (10 KB) , Nov. 10, 2009 [Editors Note: Lisa Lecas from the AMA Media Relations department sent a Nov. 12, 2009 email to ProCon.org with the following statement explaining the policy change: To help facilitate scientific research and the development of cannabionoid-based medicines, the AMA adopted new policy urging the federal government to review marijuanas status as a Schedule I substance. Despite more than 30 years of clinical research, only a small number of randomized, controlled trials have been conducted on smoked cannabis. Federal drug approval is achieved after appropriate scientific and regulatory review to establish safety and efficacy. The limited nature of rigorous scientific studies on the therapeutic use of cannabis is insufficient to satisfy the current standards for a prescription drug product.]
Posted on: Mon, 19 Jan 2015 00:09:28 +0000
Trending Topics
Recently Viewed Topics
© 2015